BR112017008218A2 - métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal - Google Patents

métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal

Info

Publication number
BR112017008218A2
BR112017008218A2 BR112017008218A BR112017008218A BR112017008218A2 BR 112017008218 A2 BR112017008218 A2 BR 112017008218A2 BR 112017008218 A BR112017008218 A BR 112017008218A BR 112017008218 A BR112017008218 A BR 112017008218A BR 112017008218 A2 BR112017008218 A2 BR 112017008218A2
Authority
BR
Brazil
Prior art keywords
renal
prognosis
diagnosis
compositions
methods
Prior art date
Application number
BR112017008218A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick Kampf James
Gray Jeff
Anderberg Joseph
Nakamura Kevin
Mcpherson Paul
Kwan Thomas
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of BR112017008218A2 publication Critical patent/BR112017008218A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BR112017008218A 2014-10-20 2015-10-20 métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal BR112017008218A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066316P 2014-10-20 2014-10-20
US201462066313P 2014-10-20 2014-10-20
US201462066310P 2014-10-20 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
BR112017008218A2 true BR112017008218A2 (pt) 2018-01-09

Family

ID=55761743

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008218A BR112017008218A2 (pt) 2014-10-20 2015-10-20 métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal

Country Status (13)

Country Link
US (2) US11333671B2 (https=)
EP (2) EP3968022A1 (https=)
JP (4) JP6792553B2 (https=)
KR (1) KR102431003B1 (https=)
CN (2) CN107003301B (https=)
AU (2) AU2015336069B2 (https=)
BR (1) BR112017008218A2 (https=)
CA (1) CA2965153C (https=)
EA (1) EA201790696A1 (https=)
ES (1) ES2907551T3 (https=)
MX (1) MX388231B (https=)
PT (1) PT3210018T (https=)
WO (1) WO2016064877A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107003301B (zh) 2014-10-20 2019-11-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP2020504157A (ja) * 2017-01-12 2020-02-06 アスチュート メディカル,インコーポレイテッド C−cモチーフケモカインリガンド14の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
US12114978B2 (en) 2018-04-02 2024-10-15 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
CN119454032A (zh) * 2018-04-02 2025-02-18 波特雷罗医疗公司 用于排出和分析体液并评估健康的系统、设备和方法
CN114207436A (zh) * 2019-05-24 2022-03-18 机敏医药股份有限公司 基于c-c基序趋化因子配体14测量而评估和治疗肾损伤的方法
US20230290457A1 (en) * 2020-03-23 2023-09-14 Biocogniv Inc. Artificial intelligence medical device
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
AU2021381364A1 (en) * 2020-11-18 2023-06-22 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure
WO2023168299A1 (en) * 2022-03-03 2023-09-07 Astute Medical, Inc. Methods and compositions for assessing and treating persistent acute kidney injury based on c-c motif chemokine ligand 14 measurement

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
IL163547A0 (en) * 2002-02-12 2005-12-18 Quark Biotech Inc Use of the axl receptor for diagnosis and treatment of renal disease
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
AU2006272913B2 (en) 2005-07-21 2012-01-19 The Johns Hopkins University Methods of detecting and treating acute kidney injury
CA2663749A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
WO2010048347A2 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20110065599A1 (en) * 2009-08-07 2011-03-17 Rules-Based Medicine, Inc. Methods and Devices for Detecting Kidney Damage
NZ630277A (en) * 2009-09-21 2015-02-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2496942B1 (en) 2009-11-07 2017-03-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2779905A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
PT2666872T (pt) * 2010-02-05 2016-07-08 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
NZ605698A (en) * 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2899545B1 (en) * 2010-06-23 2018-08-22 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) * 2010-06-23 2015-05-22 Astute Medical Inc
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2694974B1 (en) 2011-04-04 2015-10-21 Universiteit Gent Biomarkers for acute kidney injury
CN103874923B (zh) * 2011-08-26 2016-09-14 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
ES2734494T3 (es) * 2011-12-08 2019-12-10 Astute Medical Inc Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EP2962109A4 (en) 2013-02-26 2016-12-07 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
CN107003301B (zh) 2014-10-20 2019-11-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Also Published As

Publication number Publication date
WO2016064877A3 (en) 2016-09-09
KR20170084102A (ko) 2017-07-19
AU2022201130B2 (en) 2024-06-27
EA201790696A1 (ru) 2017-10-31
JP2017533427A (ja) 2017-11-09
JP6792553B2 (ja) 2020-11-25
EP3210018A2 (en) 2017-08-30
US20220236286A1 (en) 2022-07-28
AU2015336069A1 (en) 2017-05-25
JP7002623B2 (ja) 2022-02-10
CN110702921A (zh) 2020-01-17
US11333671B2 (en) 2022-05-17
CN107003301A (zh) 2017-08-01
EP3210018B1 (en) 2021-07-28
PT3210018T (pt) 2021-10-04
AU2022201130A1 (en) 2022-03-17
KR102431003B1 (ko) 2022-08-09
MX2017005126A (es) 2017-09-15
EP3210018A4 (en) 2018-06-20
CA2965153C (en) 2023-10-24
US20180209990A1 (en) 2018-07-26
MX388231B (es) 2025-03-19
JP2023052587A (ja) 2023-04-11
ES2907551T3 (es) 2022-04-25
JP2021039112A (ja) 2021-03-11
CA2965153A1 (en) 2016-04-28
CN110702921B (zh) 2024-02-06
US12099067B2 (en) 2024-09-24
JP7217796B2 (ja) 2023-02-03
JP2022046669A (ja) 2022-03-23
EP3968022A1 (en) 2022-03-16
CN107003301B (zh) 2019-11-01
AU2015336069B2 (en) 2021-11-25
WO2016064877A2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
BR112017008218A2 (pt) métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
BR112012032537A2 (pt) biomarcadores de câncer de pulmão e suas utilizações
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
BR112018070971A2 (pt) métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia
EP3734280A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX366653B (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
BR112014011818A2 (pt) método para realizar ensaios de quantificação
BR112016021383A2 (pt) Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
EP2585827A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
BR112018074853A2 (pt) métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
IN2014DN08537A (https=)

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements